-
Mashup Score: 2
Next meeting will be held in person and virtually during SSO 2023 in Boston, MA @ Hynes Convention Center on Wednesday March 22nd 1-5 pm EDT (GMT -4). Subscribe here to participate! Find the final …
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8JCI - 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma - 2 year(s) ago
Clinical MedicineDevelopment Open Access | 10.1172/JCI151604 Jenying Deng,1 Jianhua Ling,3 Xinqun Li,1 Yi-Ju Chiang,1 Eugene J. Koay,4 Huamin Wang,5 Jared K. Burks,6 Paul J. Chiao,3 Mark W. Hurd,7 Manoop S. Bhutani,8 Jeffrey H. Lee,8 Brian R. Weston,8 Anirban Maitra,7 Naruhiko Ikoma,1…
Source: www.jci.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @Aiims1742: #PancreaticCancer organoid based platform from @MDAndersonNews on the cover of @jclinicalinvest https://t.co/Q23EGlCyTs htt…
-
-
Mashup Score: 1
MD Anderson is Hiring! Search available jobs or submit your resume now by visiting this link. Please share with anyone you feel would be a great fit.
Source: Careers at MD AndersonCategories: Hem/Oncs, Latest HeadlinesTweet-
Apply via the job posting link and email CVs and letter of intent directly to Dr. Matthew Katz @mkatzmd and Dr. Christina Roland @CrisyRoland https://t.co/gNceEfFbG2
-
-
Mashup Score: 3The immune landscape of undifferentiated pleomorphic sarcoma - 2 year(s) ago
IntroductionUndifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune microenvironment of UPS and its association with oncologic outcomes.Material and methodsSurgically resected UPS samples were stained by…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @lazcano_rossana: The immune landscape of undifferentiated pleomorphic sarcoma https://t.co/uXYEpodXyM Check out our new paper on the i…
-
-
Mashup Score: 22
When applying to general surgery residency, I remember the most common question posed at residency Q&A sessions: “Are dedicated research years required?”. More often than not, academic programs answered with some variation of, “Usually… but not always”. The concern among medical students entering the field of surgery is valid; 5 years at a resident’s salary […]
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @AcademicSurgery: The Value of Dedicated Research Time https://t.co/ayKvlEG4BJ
-
RT @AcademicSurgery: The Value of Dedicated Research Time https://t.co/ayKvlEG4BJ
-
-
Mashup Score: 8FDA Approves New Treatment Option for Patients with ALS - 2 year(s) ago
The FDA approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with ALS, commonly referred to as Lou Gehrig’s disease.
Categories: Hem/Oncs, Latest HeadlinesTweet-
My father died of #ALS in 2020. During his journey, we were fortunate he could participate in the #clinicaltrials that led to this FDA approval yesterday. Although not a cure for him, his participation in clinical trials will help future patients. 🥰 https://t.co/9PS7MCVoQG
-
-
Mashup Score: 2
This is the first webinar of the 2022-2023 Transatlantic Australasian RetroPeritoneal Sarcoma Working Group (TARPSWG) Educational Webinar Series. We will discuss pathology, RT and surgery in patients with retroperitoneal liposarcoma and methodology of translational research in STS with leading experts in the field.
Source: Zoom Video CommunicationsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @sarresurgeon: @TARPSWG free educational webinars with world experts start tomorrow! 🙌🏻💛🌎 Make sure to register: https://t.co/uT6wak1SpA
-
-
Mashup Score: 2
This phase 2 nonrandomized clinical trial examines the association of cabazitaxel treatment for patients with advanced dedifferentiated liposarcoma with progression-free survival.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Robertasanfili: A Nonrandomized Controlled Trial of Cabazitaxel in Dedifferentiated Liposarcoma https://t.co/ytRbmuKy0r via @JAMAOnc pa…
-
-
Mashup Score: 0Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma-Are We There Yet? - PubMed - 2 year(s) ago
Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma-Are We There Yet?
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Honored to contribute this editorial @JAMAOnc discussing histology-based clinical trials in sarcoma. Moving forward but more work to do! @MDAndersonNews https://t.co/EwNxCmdDC0
-
-
Mashup Score: 2
The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute, according to two sources familiar with the decision.
Source: STATCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Fil_Bednar: The first woman to head NCI is a surgeon! How freaking cool is that! https://t.co/OcmNVEOmqz
-
RT @FioreDoc: TARPSWG semiannual meeting at SSO – Wednesday March 22nd, 1-5 pm EDT (GMT-4) https://t.co/7lm53lQjkX